'
Retatrutide is still investigational and hasnt been submitted to the MHRA, the FDA, or any other regulator for approval
Covariates We matched our statistical models for the following covariates: age, sex, T2D complications (kidney, ophthalmic, neurological, and circulatory), comorbidities (alcohol-related disorders, nicotine dependence, hypertension, dyslipidemia, T2D, overweight/obesity, hypertensive disease, cerebrovascular disease, ischemic heart disease, chronic kidney disease, chronic lower respiratory disease, neoplasms, and systemic connective tissue disorders), lipid-lowering agents (HMG-CoA reductase inhibitors, ezetimibe, evolocumab, and alirocumab), antihypertensives (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium-channel blockers, diuretics, and furosemide), anti-anginal or anti-ischemic agents (organic nitrates and ranolazine), heart failure medications (angiotensin receptor-neprilysin inhibitors, eplerenone, vericiguat, digitalis glycosides, SGLT2i, spironolactone, and ivabradine), antiplatelet drugs (aspirin, clopidogrel, ticagrelor, prasugrel, and cangrelor), hemoglobin A1c, and eGFR
dosing at steady state semaglutide 0.5 mg and 1.0 mg in subjects with T2DM is shown in Fig
